AbbVie's new schizophrenia drug fails in trials, causing a 10% drop in the company's stock.

AbbVie's experimental schizophrenia drug, emraclidine, failed in two Phase 2 trials, not meeting the goal of reducing symptoms significantly compared to a placebo. Despite the setback, which caused AbbVie's stock to drop over 10%, the company reports that the drug was well-tolerated. Investment firm Cantor Fitzgerald remains optimistic about AbbVie's stock and pipeline.

November 11, 2024
14 Articles